Screening for CGG repeat expansion in the FMR1 gene by melting curve analysis of combined 5′ and 3′ direct triplet-primed PCRs

Clinical Chemistry

Volumn 58, Issue 3, 2012, Pages 568-579

  Teo, Clara R L ^a   Law, Hai Yang ^b   Lee, Caroline G ^a,c,d   Chong, Samuel S ^a,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e University Children's Medical Institute   (Singapore)

^f NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CAPILLARY ELECTROPHORESIS; CGG REPEAT EXPANSION; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; MALE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRINUCLEOTIDE REPEAT;

FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; GENOTYPE; HUMANS; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEIC ACID DENATURATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSITION TEMPERATURE; TRINUCLEOTIDE REPEATS;

EID: 84863267277     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.174615     Document Type: Article

References (45)

1. Willemsen R, Smits A, Severijnen LA, Jansen M, Jacobs A, De Bruyn E, Oostra B. Predictive testing for cognitive functioning in female carriers of the fragile X syndrome using hair root analysis. J Med Genet 2003;40:377-9. (Pubitemid 36613479)
2. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996;64:196-7.
3. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991;66:817-22. (Pubitemid 121001715)
4. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991;67: 1047-58. (Pubitemid 121001519)
5. de Vries BB, Wiegers AM, Smits AP, Mohkamsing S, Duivenvoorden HJ, Fryns JP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996;58:1025-32. (Pubitemid 26115174)
6. Spector EB, Kronquist K. Technical standards and guidelines for fragile X testing: a revision to the disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of Medical Genetics. http://www.acmg.net/Pages/ACMG-Activities/stds-2002/fx.htm (Accessed December 2011).
7. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97: 189-94. (Pubitemid 32059206)
8. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004; 291:460-9. (Pubitemid 38129750)
9. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-30. (Pubitemid 32634862)
10. Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 2009;11:306-10.
11. Bennett CE, Conway GS, Macpherson JN, Jacobs PA, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum Reprod 2010;25:1335-8.
12. Rebar RW. Premature ovarian failure. Obstet Gynecol 2009;113:1355-63.
13. Bailey DB, Skinner D, Hatton D, Roberts J. Family experiences and factors associated with the diagnosis of fragile X syndrome. J Dev Behav Pediatr 2000;21:315-21.
14. Lachiewicz AM, Dawson DV, Spiridigliozzi GA. Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet 2000; 92:229-36. (Pubitemid 30252665)
15. Rousseau F, Labelle Y, Bussieres J, Lindsay C. The fragile X mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev 2011; 32:135-62.
16. Strom CM. Population-based carrier screening and prenatal diagnosis. MLO Med Lab Obs 2004; 36:12-7; quiz 20-1.
17. Saul RA, Friez M, Eaves K, Stapleton GA, Collins JS, Schwartz CE, Stevenson RE. Fragile X syndrome detection in newborns-pilot study. Genet Med 2008;10:714-9.
18. Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005;192:1905-12; discussion 1912-5.
19. Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003;7:1-106.
20. Skinner D, Sparkman KL, Bailey DB Jr. Screening for fragile X syndrome: parent attitudes and perspectives. Genet Med 2003;5:378-84. (Pubitemid 37264987)
21. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3:359-71.
22. Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 1999;7: 212-6. (Pubitemid 29150232)
23. Warner JP, Barron LH, Goudie D, Kelly K, Dow D, Fitzpatrick DR, Brock DJ. A general method for the detection of large CAG repeat expansions by fluorescent PCR. J Med Genet 1996;33:1022-6.
24. Amos Wilson J, Pratt VM, Phansalkar A, Muralidharan K, Highsmith WE Jr, Beck JC, et al. Consensus characterization of 16 FMR1 reference materials: a consortium study. J Mol Diagn 2008; 10:2-12. (Pubitemid 351184830)
25. ngenotype classification using a methylation specific triple PCR assay. J Med Genet 2004;41:e45.
26. Lyon E, Laver T, Yu P, Jama M, Young K, Zoccoli M, Marlowe N. A simple, high-throughput assay for fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn 2010;12:505-11.
27. n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening. Genet Med 2010;12:162-73.
28. Chen L, Hadd A, Sah S, Filipovic-Sadic S, Krosting J, Sekinger E, et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for Southern blot analysis. J Mol Diagn 2010;12:589-600.
29. Ross LF, Acharya K. Policy considerations in designing a fragile X population screening program. Genet Med 2008;10:711-3.
30. Musci TJ, Moyer K. Prenatal carrier testing for fragile X: counseling issues and challenges. Obstet Gynecol Clin North Am 2010;37:61-70.
31. de Graaff E, Rouillard P, Willems PJ, Smits AP, Rousseau F, Oostra BA. Hotspot for deletions in the CGG repeat region of FMR1 in fragile X patients. Hum Mol Genet 1995;4:45-9.
32. Acharya K, Ross LF. Fragile X screening: attitudes of genetic health professionals. Am J Med Genet A 2009;149A:626-32.
33. Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile X syndrome: findings from a national parent survey. Pediatrics 2009;124:527-33.
34. Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics 2008;121:e693-704.
35. Xuncla M, Badenas C, Dominguez M, Rodriguez-Revenga L, Madrigal I, Jimenez L, et al. Fragile X syndrome prenatal diagnosis: parental attitudes and reproductive responses. Reprod Biomed Online 2010;21:560-5.
36. Botkin JR. Newborn screening for fragile X syndrome: Do we care what parents think? Pediatrics 2011;127:e1593-4.
37. Nolin SL, Glicksman A, Ding X, Ersalesi N, Brown WT, Sherman SL, Dobkin C. Fragile X analysis of 1112 prenatal samples from 1991 to 2010. Prenat Diagn 2011;31:925-31.
38. Skinner D, Choudhury S, Sideris J, Guarda S, Buansi A, Roche M, et al. Parents' decisions to screen newborns for FMR1 gene expansions in a pilot research project. Pediatrics 2011;127: e1455-63.
39. Levenson D. A majority of parents accept newborn screening for fragile X. Am J Med Genet A 2011;155A:viii-ix.
40. Elias MH, Ankathil R, Salmi AR, Sudhikaran W, Limprasert P, Zilfalil BA. A new method for FMR1 gene methylation screening by multiplex methylation-specific real-time polymerase chain reaction. Genet Test Mol Biomarkers 2011;15: 387-93.
41. Dahl C, Gronskov K, Larsen LA, Guldberg P, Brondum-Nielsen K. A homogeneous assay for analysis of FMR1 promoter methylation in patients with fragile X syndrome. Clin Chem 2007; 53:790-3. (Pubitemid 46580255)
42. Strom CM, Crossley B, Redman JB, Buller A, Quan F, Peng M, et al. Molecular testing for fragile X syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med 2007;9:46-51. (Pubitemid 46105847)
43. Chen L, Hadd AG, Sah S, Houghton JF, Filipovic-Sadic S, Zhang W, et al. High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel FMR1 methylation patterns undetected in Southern blot analyses. Genet Med 2011;13:528-38.
44. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 2010;56:399-408.
45. Hill MK, Archibald AD, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genet Med 2010;12:396-410.